 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. Zymeworks or the Company NYSE: ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks proprietary AzymetricTM platform, with Jazz Pharmaceuticals plc NASDAQ:JAZZ. 